Inovio Offering Grosses $24.3M for DNA Vaccine Trials

Inovio Pharmaceuticals Inc. expects to gross $24.3 million in an offering of 21.1 million shares of common stock packaged with 10.5 million warrants priced at $1.15 a unit, 11.5 percent below the stock's closing price of $1.30 last Friday. The Blue Bell, Pa.-company said it expects to net $23 million.